LEADER 05305nam 2200661Ia 450 001 9910146238203321 005 20170809173147.0 010 $a1-280-52069-8 010 $a9786610520695 010 $a3-527-60569-X 010 $a3-527-60190-2 035 $a(CKB)1000000000019364 035 $a(EBL)482198 035 $a(OCoLC)68963365 035 $a(SSID)ssj0000229854 035 $a(PQKBManifestationID)11947191 035 $a(PQKBTitleCode)TC0000229854 035 $a(PQKBWorkID)10177634 035 $a(PQKB)10038288 035 $a(MiAaPQ)EBC482198 035 $a(EXLCZ)991000000000019364 100 $a20030725d2004 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aPseudo-peptides in drug discovery$b[electronic resource] /$f[edited by] Peter E. Neilsen 210 $aWeinheim $cWiley-VCH$dc2004 215 $a1 online resource (258 p.) 300 $aDescription based upon print version of record. 311 $a3-527-30633-1 320 $aIncludes bibliographical references and index. 327 $aPseudo-peptides in Drug Discovery; Contents; Preface; List of Contributors; 1 Versatile Oligo(N-Substituted) Glycines: The Many Roles of Peptoids in Drug Discovery; 1.1 Introduction; 1.2 Peptoid Synthesis; 1.2.1 Solid-Phase Synthesis; 1.2.2 Sub-monomer Solid-Phase Method; 1.2.3 Side Reactions; 1.2.4 Post-Synthetic Analysis; 1.3 Drug Discovery via Small-Molecule Peptoid Libraries; 1.3.1 Peptoid Drugs from Combinatorial Libraries; 1.3.2 Peptoid Inhibitors of RNA-Protein Interactions; 1.4 Peptoid-Based Drug Delivery and Molecular Transporters: Cellular Uptake 327 $a1.4.1 Peptoid Mimics of HIV-Tat Protein1.4.2 Cellular Delivery of Nucleic Acids; 1.5 Peptoid Mimics of Peptide Ligands; 1.6 Peptoids with Folded Structure; 1.6.1 Restricting Conformational Space; 1.6.2 Peptoid Helices; 1.6.2.1 CD and NMR Studies of a Helical Peptoid Pentamer with ?-Chiral Aromatic Side Chains; 1.6.2.2 CD Studies of Longer Peptoid Helices Containing ?-Chiral Aromatic Side Chains; 1.6.2.3 Structural Studies of Peptoids with Aliphatic Side Chains by CD, NMR, and X-ray Crystallography; 1.6.2.4 Summary; 1.6.3 Protein-mimetic Structures 327 $a1.7 Biomimetic Peptoid Structures for Therapeutic Applications1.7.1 Peptoid Mimics of Antibacterial Peptides; 1.7.2 Peptoid-Based Mimics of Lung Surfactant Proteins; 1.7.3 Collagen-based Structures Containing Peptoid Residues; 1.8 Obstacles to the Development of Biomedically-useful Peptoids; 1.8.1 Enhance the Diversity of Secondary Structure in Peptoid Foldamers; 1.8.2 Improve Understanding of Peptoid Sequence/Structure Relationships; 1.8.3 Translate Bioactive Peptide Sequences into Bioactive Peptoid Sequences; 1.8.4 Develop Peptoids with Stable Tertiary Structure 327 $a1.8.5 Develop Peptoid Shuttles for Intracellular Import of Xenobiotic Agents1.8.6 Optimize Pharmacological Profile of Oligopeptoids; 1.9 Conclusion; 1.10 References; 2 ?-Peptides, ?-Peptides and Isosteric Backbones: New Scaffolds with Controlled Shapes for Mimicking Protein Secondary Structure Elements; 2.1 Introduction; 2.2 Molecular Organization in ?-Peptide Oligomers; 2.2.1 Historical Background; 2.2.2 ?-Amino Acids versus ?-Amino Acids: An Enormous Increase in Chemical Diversity; 2.2.3 Helical Folds; 2.2.3.1 The 3(14)-Helix; 2.2.3.2 The 12/10- (10/12-) Helix; 2.2.3.3 The 2.5(12)-Helix 327 $a2.2.3.4 The 2(8)-Helix2.2.4 Extended ?-Peptide Strands, Turns and Formation of Sheet Structures; 2.3 Molecular Organization in ?-Peptide Oligomers; 2.3.1 Preparation of ?-Amino Acid Monomers for ?-Peptide Synthesis; 2.3.2 Helical Folds; 2.3.3 Turn and Sheet Structures; 2.4 Biological Activities of ?- and ?-Peptides; 2.4.1 Biological Stability; 2.4.2 Bioactive Peptides Based on Helical Scaffolds; 2.4.3 Bioactive Peptides Based on Open-Chain ?-Turn Mimetics; 2.4.4 Cell Penetrating ?-Peptides; 2.5 Isosteres; 2.5.1 Example 1: Oligomers of ?-Aminooxy Acids as ?-Peptide Mimetics 327 $a2.5.2 Example 2: N,N ?-Linked Oligoureas as ?-Peptide Mimetics 330 $aPeptides are among the most versatile bioactive molecules, yet the do not make good drugs, because they are quickly degraded or modified in the body.To overcome this problem, stable and at the same time biologically active pseudo-peptides have been developed. These novel compounds open up new perspectives in drug design by providing an entire range of highly specific and non-toxic pharmaceuticals.This is the first work devoted to the topic and draws together knowledge gained on different types of peptidomimetics and other pseudo-peptides with drug properties. As such, it includes pepto 606 $aPeptide drugs$xDesign 606 $aPeptides 606 $aAmino acids$xSynthesis 606 $aPolyamides 608 $aElectronic books. 615 0$aPeptide drugs$xDesign. 615 0$aPeptides. 615 0$aAmino acids$xSynthesis. 615 0$aPolyamides. 676 $a615.19 701 $aNielsen$b Peter E.$f1951-$0970547 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910146238203321 996 $aPseudo-peptides in drug discovery$92205961 997 $aUNINA